Targeted cancer therapy requires knowledge of driver aberrations. Here the authors perform large-scale transcriptome analysis, and show that gene fusions in NRG1, NF1and Hippo pathway genes are recurrent mostly among lung cancers lacking known driver mutations.
- Saravana M. Dhanasekaran
- O Alejandro Balbin
- Arul M. Chinnaiyan
